These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 30256029)

  • 1. Undetectable Serum Levels of Anti-Müllerian Hormone in Women with Ovarian Hyperstimulation Syndrome During In Vitro Fertilization and Successful Pregnancy Outcome: Case Report.
    Grbavac I; Zec I; Ljiljak D; Rakoš Justament R; Bukovec Megla Ž; Kuna K
    Acta Clin Croat; 2018 Mar; 57(1):177-180. PubMed ID: 30256029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Value of anti-Müllerian hormone in predicting pregnant outcomes of polycystic ovary syndrome patients undergone assisted reproductive technology].
    Li Y; Tan JQ; Mai ZY; Yang DZ
    Zhonghua Fu Chan Ke Za Zhi; 2018 Jan; 53(1):23-30. PubMed ID: 29374882
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of myo-inositol/di-chiro-inositol on markers of ovarian reserve in women with PCOS undergoing IVF/ICSI: A systematic review and meta-analysis.
    Bhide P; Pundir J; Gudi A; Shah A; Homburg R; Acharya G
    Acta Obstet Gynecol Scand; 2019 Oct; 98(10):1235-1244. PubMed ID: 30993683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Associated with Ovarian Hyperstimulation Syndrome (OHSS) Severity in Women With Polycystic Ovary Syndrome Undergoing IVF/ICSI.
    Sun B; Ma Y; Li L; Hu L; Wang F; Zhang Y; Dai S; Sun Y
    Front Endocrinol (Lausanne); 2020; 11():615957. PubMed ID: 33542709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Müllerian hormone dynamics during GNRH-antagonist short protocol for IVF/ICSI in women with varying ovarian reserve levels.
    Melado Vidales L; Fernández-Nistal A; Martínez Fernández V; Verdú Merino V; Bruna Catalán I; Bajo Arenas JM
    Minerva Ginecol; 2017 Apr; 69(2):128-134. PubMed ID: 27310675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dynamics of serum anti-Mullerian-hormone levels during controlled ovarian hyperstimulation with GnRH-antagonist short protocol in polycystic ovary syndrome and low responders.
    Weintraub A; Margalioth EJ; Chetrit AB; Gal M; Goldberg D; Alerhand S; Eldar-Geva T
    Eur J Obstet Gynecol Reprod Biol; 2014 May; 176():163-7. PubMed ID: 24630573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum anti-Mullerian hormone assessment of ovarian reserve and polycystic ovary syndrome status over the reproductive lifespan.
    Tremellen K; Zander-Fox D
    Aust N Z J Obstet Gynaecol; 2015 Aug; 55(4):384-9. PubMed ID: 26230428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.
    Magnusson Å; Nilsson L; Oleröd G; Thurin-Kjellberg A; Bergh C
    Hum Reprod; 2017 Apr; 32(4):811-819. PubMed ID: 28175316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negligible serum anti-müllerian hormone: pregnancy and birth after a 1-month course of an oral contraceptive, ovarian hyperstimulation, and intracytoplasmic sperm injection.
    Tocci A; Ferrero S; Iacobelli M; Greco E
    Fertil Steril; 2009 Jul; 92(1):395.e9-395.e12. PubMed ID: 19410249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Predictive value of anti-Mullerian hormone levels in serum and follicle fluid for IVF-ET outcomes in patients with polycystic ovarian syndrome].
    Chen X; Yin M; Ye D; He Y; Chen S
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Apr; 33(4):546-9. PubMed ID: 23644117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between serum AMH levels and IVF/ICSI outcomes in patients with polycystic ovary syndrome: a systematic review and meta-analysis.
    Yuwen T; Yang Z; Cai G; Feng G; Liu Q; Fu H
    Reprod Biol Endocrinol; 2023 Oct; 21(1):95. PubMed ID: 37872575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An AMH-based FSH dosing algorithm for OHSS risk reduction in first cycle antagonist protocol for IVF/ICSI.
    Sopa N; Larsen EC; Westring Hvidman H; Andersen AN
    Eur J Obstet Gynecol Reprod Biol; 2019 Jun; 237():42-47. PubMed ID: 31009858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro maturation versus IVF with GnRH antagonist for women with polycystic ovary syndrome: treatment outcome and rates of ovarian hyperstimulation syndrome.
    Das M; Son WY; Buckett W; Tulandi T; Holzer H
    Reprod Biomed Online; 2014 Nov; 29(5):545-51. PubMed ID: 25262236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follicular aspiration during the selection phase prevents severe ovarian hyperstimulation in patients with polycystic ovary syndrome who are undergoing in vitro fertilization.
    Zhu WJ; Li XM; Chen XM; Zhang L
    Eur J Obstet Gynecol Reprod Biol; 2005 Sep; 122(1):79-84. PubMed ID: 16154042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting the outcome of different protocols of in vitro fertilization with anti-Muüllerian hormone levels in patients with polycystic ovary syndrome.
    Chen Y; Ye B; Yang X; Zheng J; Lin J; Zhao J
    J Int Med Res; 2017 Jun; 45(3):1138-1147. PubMed ID: 28449632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study on clinical effect on infertility women with polycystic ovary syndrome treated by in vitro maturation and in vitro fertilization-embryo transfer].
    Yu R; Lin J; Zhao JZ; Wang PY; Xiao SQ; Zhang W
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):250-4. PubMed ID: 22781109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Müllerian hormone levels to predict oocyte maturity and embryo quality during controlled ovarian hyperstimulation.
    Melado Vidales L; Fernández-Nistal A; Martínez Fernández V; Verdú Merino V; Bruna Catalán I; Bajo Arenas JM
    Minerva Ginecol; 2017 Jun; 69(3):225-232. PubMed ID: 27352270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of dyslipidemia on IVF/ICSI pregnancy outcome in patients with polycystic ovary syndrome].
    Li X; Ding W; Liu JY; Mao YD; Huang J; Wang W; Ma X
    Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):402-408. PubMed ID: 29961283
    [No Abstract]   [Full Text] [Related]  

  • 19. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist--gonadotropin treatment.
    Peñarrubia J; Fábregues F; Manau D; Creus M; Casals G; Casamitjana R; Carmona F; Vanrell JA; Balasch J
    Hum Reprod; 2005 Apr; 20(4):915-22. PubMed ID: 15665015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research on the protocol of limited ovarian stimulation to prevent ovarian hyperstimulation syndrome].
    Zhu YM; Gao HJ; He RH; Huang HF
    Zhonghua Fu Chan Ke Za Zhi; 2006 Nov; 41(11):740-4. PubMed ID: 17327030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.